The company aims to increase the adoption of non-invasive imaging technologies by offering gene products and services that accelerate the development of viro-immunooncology drugs. Imanis provides recombinant oncolytic viruses for research and imaging technology for long-term cell and virus tracking studies, allowing clients to use non-invasive in vivo imaging in preclinical and clinical research.